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Quantitative immunoelectron microscopy of type VI collagen is the predominant cause of mesangial expansion [2].
in glomeruli in type I diabetic patients. The latter is the major structural change most closely
Background. The nature of the extracellular matrix (ECM) related to the clinical manifestations of diabetic nephrop-accumulating in the glomerular basement membrane (GBM)
athy (DN) in type I diabetic patients, including increasingand mesangium (Mes) in diabetes is unknown. Type IV collagen
albuminuria, hypertension, and declining glomerular fil-(Col IV) as estimated by quantitative immunoelectron micros-
copy was reduced in type I diabetic patients (D) with rapid tration rate (GFR) [1]. The a1 and a2 chains of type IV
(“fast-track”) compared with slow (“slow-track”) development collagen (Col IV), the main component of glomerular
of diabetic nephropathy (DN) lesions and controls (C). Col VI ECM, are decreased in density in the inner layer (IL)is another ECM component suggested to account for Mes matrix
of the GBM and in mesangial matrix (MM) in the type(MM) expansion in DN.
1 diabetic patient with rapid (“fast-track”) as comparedMethods. Col VI ECM density was evaluated in eight “slow-
track” {Mes fractional volume [Vv(Mes/glom)] ,0.32, duration with slow (“slow-track”) development of DN lesions and
.20 years} and seven “fast-track” patients [Vv(Mes/glom) with normal controls [3]. On the other hand, type VI
.0.37, duration ,20 years diabetes] and in eight C. Quantita- collagen, studied by immunohistochemistry, has been
tive immunoelectron microscopy was performed using poly-
reported to be increased in MM of human diabetic kid-clonal antibodies to Col VI. Gold particle density (PDG) in
ney and has been suggested as another ECM componentMM and the inner layer (IL) of the GBM was measured using
stereologic methods. that could account for mesangial expansion in DN [4, 5].
Results. GBM IL PDG was decreased in both fast-track (1.7 6 Mohan, Carter, and Spiro reported a quantitative in-
1.6/mm2, mean 6 SD, P , 0.002) and slow-track (3.9 6 2.4, crease of type VI collagen in ECM isolated from glomer-
P , 0.02) D versus C (10.8 6 7.9). GBM IL PDG was also uli of diabetic patients [6].lower in the fast-track versus slow-track D (P , 0.04). Mes
matrix PDG/mm2 was decreased in fast-track D (3.2 6 3.6) versus
C (14.1 6 14.6, P , 0.02); a similar trend was seen in slow-
METHODStrack D (5.7 6 5.6, P , 0.1). There was no significant difference
in MM PDG between the slow-track and fast-track D. Patients
Conclusion. Col VI density in MM and GBM is decreased
All studies were approved by the Committee on thein diabetic patients with slowly and rapidly developing renal
Use of Human Subjects in Research at the Universitylesions. This leaves the nature of ECM accumulation in DN
unexplained. At least in part, glomerular ECM compositional of Minnesota (Minneapolis, MN, USA), and subjects,
change is related to diabetes per se and may be independent including the normal controls (discussed later in this
of the severity of lesions. article), were enrolled only after informed consent had
been provided. Type I diabetic patients were selected
from a subset of patients that had tissue appropriately
Diabetic glomerulopathy is characterized by extracel- fixed at the time of renal biopsy for immunogold electron
lular matrix (ECM) accumulation, which results in glo- microscopy. All patients with such tissues who met the
merular basement membrane (GBM) thickening [1] and inclusion criteria were studied. The criteria were based
on severity of glomerular lesions determined by morpho-
metric analysis and on duration of diabetes in order to
Key words: insulin-dependent diabetes mellitus, renal lesions, extracel-
create two nonoverlapping groups as follows: (1) slow-lular matrix, mesangial matrix, gold particle density, glomerular base-
ment membrane. track patients (N 5 8), duration of diabetes .20 years,
mesangial fractional volume [Vv(Mes/glom)] ,0.32; andReceived for publication February 29, 2000
(2) fast-track patients (N 5 7), duration of diabetes ,20and in revised form July 7, 2000
Accepted for publication August 7, 2000 years, Vv(Mes/glom) .0.37. One fast-track patient, 26
years of age at onset, did not require insulin treatmentÓ 2001 by the International Society of Nephrology
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Table 1. Clinical characteristics of the three groups
Age Duration
Gender MBP CCr AERa
M/F years mm Hg mL/min/1.73 m2 lg/min
Normal controls (N 5 8) 1/7 48611
“Slow-track” type I (N 5 8) 3/5 3468 2765 9465 124630 13.7 (3.5–27.5)
“Fast-track” type I (N 5 7) 1/6 3265 1462 9564 60618 556.7 (67.1–3438.0)
P-value “Slow” vs. “Fast” NS ND NS ,0.001 0.003b
Abbreviations are: MBP, mean blood pressure; CCr, creatinine clearance; AER, urinary albumin excretion rate; M/F, male/female; NS, not significant; ND, not
done because variable used as a selection criterion.
a Data are median (range)
b Nonparametric test
Table 2. Morphometric analysis of the three groups
MGV GBM width Vv(Mes/glom) Vv(MM/glom)
Normal controls (N 5 69) 2.060.6a 342645 0.2060.03 0.0960.01
“Slow-track” type 1 (N 5 8) 1.860.5b 5236103 0.2760.03 0.1660.03
“Fast-track” type 1 (N 5 7) 2.360.5 7026193 0.4960.07 0.3060.05
P-value ANOVA ,0.001 ,0.001 ,0.001 ,0.001
NC vs. “Slow” NS ,0.001 ,0.001 ,0.001
NC vs. “Fast” ,0.001 ,0.001 ,0.001 ,0.001
“Slow” vs. “Fast” NS ,0.05 ND ,0.001
Abbreviations are: MGV, mean glomerular volume (3106 mm3); GBM width, glomerular basement membrane width (nm); Vv(Mes/glom), volume fraction of
mesangium; Vv(MM/glom), volume fraction of mesangial matrix; NC, normal controls; NS, not significant; ND, not done because variable used as a selection criterion.
a MGV in controls, N 5 20; in “slow track,” N 5 7
until three years after the diagnosis of diabetes, but was are presented as the means of these multiple estimates
of albumin excretion rate (AER). Microalbuminuria andinsulin dependent thereafter until he underwent success-
ful kidney-pancreas transplantation 12 years after diabe- overt nephropathy were defined as AER over 20 mg/min
and over 200 mg/min, respectively. Creatinine was mea-tes onset. All other diabetic patients had a typical onset
of type I diabetes. Because in our experience there is sured by the Jaffe´ method, and creatinine clearances
(CCr) were performed by standard laboratory proceduresextensive glomerular and interstitial scarring in type I
diabetic patients with advanced renal insufficiency, no on the above 24-hour urine collections. Blood pressure
(BP) was taken by the trained CRC nursing staff ac-patients were included whose serum creatinine was .1.5
mg/dL or whose GFR as estimated by creatinine clear- cording to standard protocols over the five to seven days
of the CRC admissions.ance was ,50 mL/min/1.73 m2.
Controls Renal structural measurements
Renal tissue obtained by percutaneous needle biopsyBiopsy tissues from two sets of controls were obtained
from normal kidney donors at the time of transplantation in the type I diabetic patients or by needle biopsy at
transplant surgery in the controls was immediately exam-surgery: (1) Eight controls were used to quantitate the
normal glomerular patterns of type VI collagen; and (2) 69 ined using a dissecting microscope to ensure that glomer-
uli were in the tissue samples.age-matched controls were used to obtain the reference
values for the light (LM) and electron microscopic (EM) Mean glomerular volume (MGV). The point-counting
method of Weibel and Gometz was used to measuremorphometric measurements. Demographics and clini-
cal characteristics of the first set of normal controls and MGV on LM tissues, which were fixed in Zenker’s solu-
tion, embedded in paraffin, sectioned, and stained withthe fast-track and slow-track type I diabetic patient
groups are presented in Table 1. Morphometric analyses periodic acid-Schiff (PAS) [8]. Tissue for MGV was
available in 20 out of 69 normal controls, 7 out of 8 slow-of the second set of normal controls and the two type I
diabetic patient groups are presented in Table 2. track, and 7 out of 7 fast-track patients. Fifteen to 75
(31 6 19, mean 6 SD) glomerular profiles per sample
Laboratory and clinical measurements were measured to determine MGV.
Conventional electron microscopy. Routine stereologicUrinary albumin was measured by nephelometry using
at least two, and usually three, 24-hour sterile urine sam- techniques, previously described in detail [1, 9, 10], were
used to measure GBM width, Vv(Mes/glom), and mesan-ples carefully collected in the Clinical Research Center
(CRC) at the University of Minnesota. Data (in mg/min) gial matrix fractional volume [Vv(MM/glom)] in non-
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sclerosed glomeruli. Briefly, GBM width was measured the limits of the lamina rara externa, lamina densa, and
using the orthogonal intercept method [10]. Vv(Mes/glom) lamina rara interna could not be precisely determined on
and Vv(MM/glom) were measured by counting the number the photographs. Therefore, the outer and inner thirds
of points falling on the mesangium (Mes) and mesangial of the GBM contain not only lamina rara externa and
matrix, respectively, and dividing by the number of points interna, respectively, but also some of the lamina densa
falling on the reference area, the glomerular tuft [1, 2]. [3]. A grid consisting of 0.8 cm squares was superimposed
Preparation of tissues for immunogold electron micros- on each photograph. The area of each zone of peripheral
copy. Small 1 mm3 cubes of cortical kidney tissue were GBM sampled was estimated by adding the number of
immediately fixed in 4% periodate-lysine paraformalde- squares in which the lower left hand corner intersected
hyde solution for one hour at 48C and were then washed a given GBM zone. All of the gold particles labeling each
with 0.025 mol/L phosphate buffer containing 6% su- zone of the GBM were then counted, and the density
crose [3, 11]. The samples were dehydrated in a graded (particles/mm2) was calculated.
series of ethanols at progressively lower temperatures, Because previous reports showed that type VI colla-
down to 2358C, and embedded in Lowicryl K4M and gen was mainly located along the subendothelial aspect
polymerized with long wave ultraviolet radiation. Ultra of the GBM in normal controls [13, 14], only the particles
thin sections were cut and mounted on Formvar-coated in the GBM inner zone were counted and compared
nickel grids. First, the grids were immersed in 10% nor- among the study groups.
mal goat serum for 30 minutes at room temperature. Mesangial matrix. Mesangial GBM was defined as that
The grids were then incubated overnight at 48C with part of the GBM in which one side was covered with
primary antibody (rabbit anti-human type VI collagen epithelial cells and the other side interfaced with mesan-
antibody; Chemicon International Inc., Temecula, CA, gial matrix or mesangial cells. The boundary between
USA). This antibody reacts with human and bovine type mesangial GBM and the Mes was roughly drawn to ex-
VI collagen by enzyme-linked immunosorbent assay tend from the endothelial edge of the peripheral GBM,
(ELISA). The less than 10% cross-reactivity with other approximating the width of the peripheral GBM, and
collagens was removed by absorption with types I, II, paralleling the epithelial edge of the mesangial GBM [1].
III, IV, and V collagens immobilized on Sepharose 4B Matrix material internal to these boundaries and to endo-
prior to purification of the antiserum. Excess unbounded thelial cells was considered to be mesangial matrix. Non-
primary antibody was then washed off using phosphate- matrix material was considered mesangial cells. Because
buffered saline (PBS) containing 1% bovine serum albu- mesangial matrix particles were too time consuming to
min (BSA), 0.05% Tween 20, and 0.7% NaCl. After- count in their entirety, an unbiased sampling strategy
ward, they were incubated with 10 nm gold-conjugated
was used. A grid consisting of 1 cm squares was used to
goat anti-rabbit IgG Cr secondary antibody diluted 1:10
define the area of mesangial matrix in which the typein PBS 1 1% BSA for four hours at room temperature
VI collagen particles were counted. The area of eachand washed, first with PBS 1 1% BSA 1 0.05% Tween
component sampled was determined by counting the20 and then with water. The sections were then stained
number of squares in which the lower left hand cornerwith uranyl acetate for 10 minutes and lead citrate for
fell on a given component. The number of gold particles5 minutes. Observation was performed with a JEOL 100
labeling a given component within that square was thenCX electron microscope (Tokyo, Japan). Twenty to 50
counted, excluding particles touching the upper and rightphotographs of each nonsclerosed glomerulus were taken
sides of the square. Some squares in which the left lowerusing an unbiased systematic sampling method and en-
hand corner fell on cells also contained mesangial matrixlarged to a final magnification of approximately 344,000.
material. Particles on matrix in these squares were as-There was no specific binding using the secondary anti-
signed to squares defined as matrix, which also containedbody and omitting the primary antibody, or by using
cellular materials. Total particles per glomerulus in therabbit anti-human insulin as the primary antibody on
peripheral GBM inner zone were not calculated sincediabetic and normal control tissues.
the peripheral GBM surface diminishes as mesangialMeasurement of gold particle densities. The density of
fractional volume increases [1]. Total particles per glo-labeling was expressed as the number of gold particles
merulus in mesangial matrix was calculated as the prod-per unit area (particles/mm2).
uct of MGV, Vv(MM/glom), and mesangial matrix parti-Peripheral GBM. Peripheral GBM was defined as that
cles density.part of the GBM covered on one side by epithelial cells
Background density. The grids for peripheral GBMand on the other side by endothelial cells with no interpo-
and mesangial matrix were also used to calculate thesition of mesangial cells or matrix [12]. Segments of pe-
density of background particles. The density of gold par-ripheral GBM were randomly selected and arbitrarily
ticles within glomerular capillary luminal and urinarydivided into three zones of approximately equal width
(outer, middle, and inner zones). This was done because spaces was calculated from squares totally within those
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spaces and was expressed as background density and both diabetic groups and was significantly higher in fast-
subtracted from the densities in the other locations [3]. track versus slow-track patients. Vv(Mes/glom) was sig-
nificantly increased in both slow-track and fast-track pa-
Relative quantitation tients compared with normal controls. The two diabetic
Immunogold density values derived here are not pre- groups differed in Vv(Mes/glom) by design. Vv(MM/glom)
sumed to represent an exact concentration of the antigen was increased in both slow-track and fast-track patients
in a glomerular ECM sites since (1) there is probably compared with normal controls and was much greater
not a 1:1 ratio of gold particles to IgG molecules; (2) in fast-track compared with the slow-track type I diabetic
there are differences in antibody affinities and/or titers; patients.
and (3) there may be a partial denaturation of antigenic
Immunogold studiessites by fixation and embedding. To minimize potential
problems caused by minor day-to-day variations in fixa- Qualitative findings. Type VI collagen gold particles
tion schedules, embedding media and incubation proto- in the normal controls were located in the peripheral
cols, one normal biopsy was randomly selected to be GBM, primarily along the inner layer. These particles
used as a control to be run each time. Gold particle were also evenly distributed throughout the normal mes-
densities were corrected by multiplying the densities angial matrix. The patterns of distribution of gold parti-
counted for a set of tissues studied at a given time by cles in both slow-track and fast-track type I diabetic
ratio of the control value first obtained and the control patients in peripheral GBM and Mes were similar to
value obtained with that set of tissues. The particle den- those seen in controls.
sity of each region was used to obtain this ratio. Quantitative findings. The density of type VI collagen
particles in the peripheral GBM inner zone was signifi-Statistics
cantly decreased in both the fast-track (1.7 6 1.6, P ,
Labeling densities for an inner zone of the peripheral 0.002) and the slow-track (3.9 6 2.4, P , 0.02) type I
GBM and mesangial matrix were compared by analysis diabetic patients compared with the controls (10.8 6 7.9;
of variance (ANOVA), and differences between groups
Fig. 1). Particle density was also significantly lower in
were analyzed by nonparametric tests. Data of morpho-
this site in the fast-track compared with the slow-trackmetry were compared by ANOVA, and differences be-
type I diabetic patients (P , 0.04). The density of type VItween groups were analyzed by nonpaired t tests. Data
collagen particles in mesangial matrix was significantlyare presented as mean 6 SD. P , 0.05 was considered
decreased in the fast-track patients (3.2 6 3.6) comparedsignificant. Values of 0.05 , P , 0.10 in two-tailed tests
with the normal controls (14.1 6 14.6, P , 0.02), whilewere considered indicative of a trend. AER was pre-
a similar trend was seen in the slow-track type I diabeticsented as median and range and was compared using a
patients (5.7 6 5.6, P , 0.10; Fig. 2). There was nononparametric test because these data are not normally
significant difference in mesangial matrix particle densitydistributed.
between the slow-track and fast-track type I diabetic
patients. Mesangial matrix particles per glomerulus were
RESULTS 1.9 6 2 3 106 in controls, 1.7 6 1.6 3 106 in slow-
Clinical characteristics track patients, and 2.5 6 3.8 3 106 in fast-track patients
(ANOVA 5 0.81, P 5 NS).Five of five slow-track and six of seven fast-track type 1
diabetic patients were female, while 7 of 8 controls were
female (Table 1). The ages were not different between DISCUSSION
the two diabetic groups and were higher in controls (P 5
We applied quantitative immunohistochemistry using0.011 vs. slow-track and P 5 0.005 vs. fast-track). Dura-
unbiased sampling methods based upon stereologic prin-tion of diabetes was, by design, greater in the slow-track
ciples to examine the site-specific distribution and totype I diabetic patients and thus was not analyzed statisti-
quantitate the relative density of type VI collagen incally. CCr was lower and AER was higher in the fast-
human biopsy materials from normal and from type Itrack compared with the slow-track type I diabetic pa-
diabetic patients with slow and rapid development of atients, but by selection, no patients had CCr of ,50 mL/
crucial lesion of DN, increase in mesangial fractionalmin/1.73 m2. All slow-track patients had normal values
volume [1].of AER. In contrast, one fast-track patient was microal-
We showed that the density of type VI collagen inbuminuric, and six had overt nephropathy.
GBM and mesangial matrix was significantly reduced in
Morphometric analysis type I diabetic patients with rapidly developing mesan-
gial expansion, while similar GBM findings and a similarMean glomerular volume was not different among the
three groups (Table 2). GBM width was increased in trend for mesangial matrix were noted in insulin-depen-
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Fig. 2. Individual values of type VI collagen particle density in theFig. 1. Individual values of type VI collagen particle density in the
mesangial (Mes) matrix among the three groups.peripheral glomerular basement membrane (GBM) inner zone among
the three groups.
dent diabetes patients despite their very slow develop- ment membrane (TBM) and Bowman’s capsule and is
present in renal interstitial collagen fibrils [13–16], butment of mesangial expansion.
The present studies confirm that glomerular type VI these sites were not evaluated in the present study.
Previous nonquantitative immunofluorescence andcollagen in normal human subjects is mainly located in
mesangial matrix, but is also seen along the inner aspect immunohistochemical studies have suggested that the
amount of type VI collagen was increased in the Mes inof the GBM [13, 14]. This GBM area, which includes the
lamina rara interna, has been shown to contain molecules patients with type I and type II diabetes, especially those
with nodular lesions [4, 17–19]. Thus, Nerlich et al de-that are present in mesangial matrix but that may be
absent from the lamina densa and lamina rara externa scribed increased immunohistochemical mesangial type
VI collagen staining in advanced cases of nephropathyregions of the GBM. Thus, the a1 and a2 chains of Col
IV also localize in mesangial matrix and GBM inner among diabetic patients. However, all but 1 of 10 of
these patients, where serum creatinine was measured,layer, while a3, a4, and a5 chains of Col IV are in the
GBM outer layers but are not found in the GBM inner had values above our entry criterion of 1.5 mg/dL. These
authors also found little and only focal increases in mes-layer or mesangial matrix [3, 13, 14]. The current results
confirm earlier work from this and other laboratories angial type VI collagen localization in patients with less
severe lesions. Thus, the increased glomerular type VIand do not support those studies that failed to find type
VI collagen in human GBM [15, 16]. Thus, the inner collagen localization in the study of Nerlich et al [4] and
Makino et al [19] were mainly seen at later stages ofaspect of the GBM, in terms of ECM composition, may
represent an extension of the Mes. If this is true, it would disease than studied here. These results are not inconsis-
tent with our work, which was performed at earlier stagesnot be surprising that mesangial changes in disease states
are reflected in this area of the capillary wall. Type VI of glomerular pathology, before advanced scarring had
supervened. These earlier diabetic lesions may be morecollagen in normal people is absent from tubular base-
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important for the understanding of the pathogenesis of quantity of mesangial matrix was increased while density
per unit area of mesangial matrix was decreased, type IVDN, as progression to end-stage renal disease will not
occur but through these earlier stages of the illness. collagen may contribute somewhat to overall mesangial
matrix expansion [2]. However, the absolute amount ofMoreover, the changes of more advanced renal injury,
characterized by marked glomerular and interstitial scar- type VI particles per glomerulus mesangial matrix in the
present study was not increased in the slow-track or thering, are common to multiple renal disorders and are not
necessarily reflective of the pathogenesis of the original fast-track patients. Both of these studies emphasize that
a substantial and perhaps the major portion of mesangialinjury process. Furthermore, most of the patients in the
study of Nerlich et al [4] and all of the patients in the matrix expansion in diabetic glomerulopathy is not yet
explained. It might be hypothesized that the decreasedpaper by Makino et al [19] were type II diabetics, and
considerable evidence is accumulating that there are im- density of type VI collagen seen in diabetic patients in
this study could result from glycosylation of antigenicportant differences in the renal pathologic findings in
type II versus type I diabetes [20, 21]. epitopes in these molecules interfering with antibody
binding. This hypothesis was considered to explain theSlow-track type I diabetic patients were selected to
have relatively mild lesions despite, on average, more reduced Col IV density in our earlier work, but rejected
since six molar urea tissue pretreatments did not changethan 25 years of type I diabetes. None had microalbumi-
nuria. Nonetheless, as a group, they had GBM thickening the results [3]. These studies were not repeated here.
Candidate ECM molecules not yet quantitatively as-and mesangial expansion compared with normal con-
trols. Glomerular structure in these patients was similar sessed include type V collagen [17–19], laminin, fibro-
nectin [18], nidogen [22], chondroitin sulfate proteogly-to those of the slow-track patients in a previous study
from this laboratory, which described glomerular quanti- cans [23], and others. However, as our immunogold
studies have shown [3], immunofluorescent microscopytative immunoelectron microscopic findings for Col IV
in type I diabetic patients [3]. Type VI collagen density studies suggest to the observer that the intensity of stain-
ing is increased [18] when, in fact, the relative and abso-was significantly decreased in GBM in the slow-track
patients in the present study. Only a trend toward a lute area or volume of mesangial matrix is markedly
increased while the relative quantity of a given ECMreduction in GBM IL density for “classic” a1 and a2
chains of Col IV was found in another study from this molecule per area or volume of mesangial matrix is mod-
erately decreased. Increases in extent or intensity oflaboratory [3]. Moreover, there was increased density of
“novel” a4 chain of Col IV in the outer zone of GBM staining inferred from LM methods need to be verified
by quantitative density studies. Still, if candidate ECMin fast-track type I diabetic patients, but again, slow-
track patients were similar to controls [3]. molecules are absent, decreased or normal in the Mes
of diabetic patients with established glomerular lesionsThe current study also found a trend for decreased
type VI collagen density in mesangial matrix in slow- by immunofluorescent microscopy, they are unlikely to
account fully for mesangial matrix expansion in this dis-track patients, while this was not found for a1 and a2
chains of Col IV [3]. Thus, the current study finds subtle order. Thus, types I and III collagen are not candidate
molecules since they are absent from the Mes by immu-changes in glomerular ECM composition even in those
type I diabetic patients who probably have a low risk of nofluorescent microscopy throughout most of natural
history of diabetic renal disease. As argued previouslyprogressing to overt DN.
All fast-track patients had microalbuminuria (1 case) for type VI collagen, types I and III collagen become
evident only at very advanced stages of mesangial expan-or overt nephropathy (6 cases) despite, on average, less
than 15 years of duration of type I diabetes. These pa- sion and Kimmelstiel-Wilson nodule formation or when
glomeruli are undergoing ischemic global sclerosis [18].tients, by selection, had more severe mesangial expan-
sion than the slow-track patients. Although patients were The absence of scar collagens from all but the latest
stages of this disease is also consistent with recent obser-not selected based upon GBM width criteria, this mea-
sure was also greater than in the slow-track patients. The vations indicating that mesangial matrix expansion as
well as GBM and TBM thickening in patients with typefast-track patients showed significantly decreased type
VI collagen density in both the GBM inner zone and I diabetes is reversible by the establishment of long-term
normoglycemia following pancreas transplantation [24].mesangial matrix compared with normal controls, and
decreased density in the GBM inner zone but not in This reversal of mesangial matrix and basement mem-
brane expansion, associated with marked remodeling ofmesangial matrix compared with the slow-track patients.
Thus, moderately advanced diabetic glomerulopathy, glomerular architecture, indicates that the expansion of
these structures is not consequent to true sclerosis, whichwhich manifests as marked mesangial matrix accumula-
tion but not glomerular scarring, is associated with re- would not be expected to be reversible. Finally, it should
be mentioned that in vitro studies have documented in-duction of the density of the two major collagens that
compose normal mesangial matrix. Since the absolute creased type VI collagen mRNA levels and protein syn-
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Int 42:115–126, 1992nature of accumulating mesangial matrix and GBM ma-
14. Zhu D, Kim Y, Steffes MW, et al: Application of electron micro-terial in type I diabetic patients remains unknown. Fur- scopic immunocytochemistry to the human kidney: Distribution
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J Histochem Cytochem 42:577–584, 1994in DN are important to the understanding of this disease.
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